Inflammatory Markers in Vitiligo
Yes, inflammatory markers are elevated in vitiligo patients, particularly C-reactive protein (CRP) and novel hematological ratios like the monocyte-to-HDL ratio (MHR), though traditional markers like ESR are not routinely assessed in this condition.
Evidence for Elevated Inflammatory Markers
Multiple recent studies consistently demonstrate elevated inflammatory markers in vitiligo patients compared to healthy controls:
C-Reactive Protein (CRP)
CRP is consistently elevated in vitiligo patients across multiple studies. The most robust evidence shows CRP levels are significantly higher in active vitiligo (mean 4.46 ± 1.09 mg/L) compared to stable vitiligo (mean 3.75 ± 1.08 mg/L), with both groups showing elevation above control values 1. This finding was replicated in 2024 studies showing higher CRP levels in vitiligo patients, though some studies noted the difference was not always statistically significant when patients were on immunosuppressive therapy 2, 3, 4.
Novel Hematological Inflammatory Ratios
The 2024-2025 research reveals that MHR (monocyte-to-HDL ratio) is the most reliable readily-available marker for systemic inflammation in vitiligo, showing statistically significant elevation in vitiligo patients (p=0.03) and particularly in generalized vitiligo (p=0.02) 2. Additional elevated markers include:
- Neutrophil-to-lymphocyte ratio (NLR): Significantly elevated in vitiligo patients 2, 5
- Monocyte-to-lymphocyte ratio (MLR): Significantly higher in generalized vitiligo (p=0.03) 2, 5
- Platelet-to-lymphocyte ratio (PLR): Elevated, with significant difference between unstable and stable vitiligo 5
Cytokines and Chemokines
Beyond traditional inflammatory markers, vitiligo demonstrates elevation of:
- IL-15: Significantly elevated in both active and stable vitiligo 1
- CXCL9 and CXCL10: Significantly higher in active versus stable vitiligo, with CXCL10 particularly elevated in patients with shorter disease duration (p<0.05) 1, 3
Clinical Implications and Caveats
Important Considerations:
Treatment status significantly affects inflammatory marker levels. Patients on immunosuppressive therapy show lower mean values of IL-6 and CRP compared to untreated patients, which can confound interpretation 4. This is a critical pitfall—always document current and recent treatment history when interpreting inflammatory markers.
Disease activity matters more than disease extent. CRP correlates better with disease activity (active vs. stable) than with disease extent measured by VASI scores 1, 4. The VIDA score (vitiligo disease activity score) should guide interpretation of inflammatory markers.
MHR emerges as the most practical marker because it uses routine laboratory values (CBC and lipid panel) already available in most clinical settings, unlike specialized cytokine assays 2, 5.
ESR Status
Notably, ESR (erythrocyte sedimentation rate) is not routinely studied or recommended in vitiligo assessment. The only guideline reference discusses ESR in the context of autoinflammatory diseases and urticarial vasculitis—not vitiligo 6. ESR and CRP are recognized as comparable inflammatory markers in general medicine 7, but vitiligo-specific research focuses on CRP rather than ESR.
Practical Algorithm for Assessment
When evaluating inflammation in vitiligo:
- Order basic inflammatory markers: CRP, CBC with differential, lipid panel
- Calculate hematological ratios: MHR, NLR, MLR, PLR from routine labs
- Document treatment status: Current and recent immunosuppressive therapy affects results
- Assess disease activity: Use VIDA score clinically (Koebner phenomenon, confetti-like depigmentation, Wood's lamp findings) 8
- Interpret in context: Higher values suggest active disease; MHR and CRP most reliable for systemic inflammation 2, 1
The interferon-γ-CXCL10-CD8+ T-cell axis represents the most reproducible immune signature in vitiligo, though these specialized markers are primarily research tools rather than routine clinical tests 8.